The therapeutic potential of tumor necrosis factor for autoimmune disease: A mechanistically based hypothesis

Cellular and Molecular Life Sciences

Volumn 62, Issue 16, 2005, Pages 1850-1862

  Kodama, S ^a   Davis, M ^b   Faustman, D L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Apoptosis; Autoimmunity; NF B; TNF

Indexed keywords

BCG VACCINE; CYTOKINE RECEPTOR ANTAGONIST; FREUND ADJUVANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; CELL ACTIVATION; CLINICAL TRIAL; COLITIS; CROHN DISEASE; DEMYELINATING DISEASE; DIABETES MELLITUS; DISEASE EXACERBATION; DNA POLYMORPHISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; JUVENILE RHEUMATOID ARTHRITIS; LUPUS LIKE SYNDROME; MULTIPLE SCLEROSIS; NONHUMAN; RASH; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VASCULITIS;

ANIMALS; APOPTOSIS; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; ENZYME ACTIVATION; HUMANS; LUPUS; MICE; MICE, INBRED NOD; NF-KAPPA B; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23944435859     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-005-5022-6     Document Type: Review

References (104)

1. Klinkhoff A. (2004) Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs 64: 1267-1283
2. Feldmann M., Brennan F. M. and Maini R. N. (1996) Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440
3. Hofman F. M., Hinton D. R., Johnson K. and Merrill J. E. (1989) Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170: 607-612
4. Sandborn W. J. and Hanauer S. B. (1999) Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm. Bowel. Dis. 5: 119-133
5. Wu A. J., Hua H., Munson S. H. and McDevitt H. O. (2002) Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice. Proc. Natl. Acad. Sci. USA 99: 12287-12292
6. van Oosten B. W., Barkhof F., Truyen E., Boringa J. B., Bertelsmann F. W., von Blomberg B. M. et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531-1534
7. Anonymous (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53: 457-465
8. Sicotte N. L. and Voskuhl R. R. (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57: 1885-1888
9. Enayati P. J. and Papadakis K. A. (2005) Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J. Clin. Gastroenterol. 39: 303-306
10. Thomas C. W. Jr, Weinshenker B. G. and Sandborn W. J. (2004) Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm. Bowel. Dis. 10: 28-31
11. Vermeire S., Noman M., Van Assche G., Baert F., Van Steen K., Esters N. et al. (2003) Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125: 32-39
12. Anonymous (2003) Update on the TNF-alpha blocking agents. Food and Drug Administration (FDA). http://www.fda.gov/ohrms/dockets/ac/03/briefing/ 3930B1_01_B-TNF.briefing.pdf
13. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R. et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343: 1594-1602
14. Charles P. J., Smeenk R. J., De Jong J., Feldmann M. and Maini R. N. (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 43: 2383-2390
15. Moreland E. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J. et al. (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130: 478-486
16. Shakoor N., Michalska M., Harris C. A. and Block J. A. (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359: 579-580
17. Bleumink G. S., ter Borg E. J., Ramselaar C. G. and Ch Stricker B. H. (2001) Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 40: 1317-1319
18. Cairns A. P., Duncan M. K., Hinder A. E. and Taggart A. J. (2002) New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann. Rheum. Dis. 61: 1031-1032
19. Swale V. J., Perrett C. M., Denton C. P., Black C. M. and Rustin M. H. (2003) Etanercept-induced systemic lupus erythematosus. Clin. Exp. Dermatol. 28: 604-607
20. Jarrett S. J., Cunnane G., Conaghan P. G., Bingham S. J., Buch M. H., Quinn M. A. et al. (2003) Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J. Rheumatol. 30: 2287-2291
21. Galaria N. A., Werth V. P. and Schumacher H. R. (2000) Leukocytoclastic vasculitis due to etanercept. J. Rheumatol. 27: 2041-2044.
22. Sandborn W. J. (2001) Strategies targeting tumor necrosis factor in Crohn's disease. Acta Gastroenterol. Belg. 64: 170-172
23. Schaible T. F. (2000) Long term safety of infliximab. Can. J. Gastroenterol. 14 Suppl C: 29C-32C
24. Vermeire S., Norman M., Van Assche G., Baert F., Van Steen K., Esters N. et al. (2003) Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disese: a prospective cohort study. Gastroenterology 125: 32-39
25. Bloom B. J. (2000) Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 43: 2606-2608
26. Loetscher H., Steinmetz M. and Lesslauer W. (1991) Tumor necrosis factor: receptors and inhibitors. Cancer Cells 3: 221-226
27. Jacob C. O., Fronek Z., Lewis G. D., Koo M., Hansen J. A. and McDevitt H. O. (1990) Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 87: 1233-1237
28. Kontoyiannis D. and Kollias G. (2000) Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur. J. Immunol. 30: 2038-2047
29. Fujimura T., Hirose S., Jiang Y., Kodera S., Ohmuro H., Zhang D. et al. (1998) Dissection of the effects of tumor necrosis factor-alpha and class II gene polymorphisms within the MHC on murine systemic lupus erythematosus (SLE). Int. Immunol. 10: 1467-1472
30. Rothe H., Schuller I., Richter G., Jongeneel C. V., Kiesel U., Diamantstein T. et al. (1992) Abnormal TNF production in prediabetic BB rats is linked to defective CD45R expression. Immunology 77: 1-6
31. Grech A. P., Riminton D. S., Gabor M. J., Hardy C. L., Sedgwick J. D. and Godfrey D. I. (2000) Increased thymic B cells but maintenance of thymic structure, T cell differentiation and negative selection in lymphotoxin-alpha and TNF gene-targeted mice. Dev. Immunol. 8: 61-74
32. Aderka D., Wysenbeek A., Engelmann H., Cope A. P., Brennan F., Molad Y. et al. (1993) Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum. 36: 1111-1120
33. Gabay C., Cakir N., Moral F., Roux-Lombard P., Meyer O., Dayer J. M. et al. (1997) Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J. Rheumatol. 24: 303-308
34. Jurewicz A. M., Walczak A. K. and Selmaj K. W. (1999) Shedding of TNF receptors in multiple sclerosis patients. Neurology 53: 1409-1414
35. Cope A. P., Aderka D., Doherty M., Engelmann H., Gibbons D., Jones A. C. et al. (1992) Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 35: 1160-1169
36. Beg A. A. and Baltimore D. (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274: 782-784
37. Bohnline E., Lowenthal J. W., Siekevitz M., Franza B. R. and Greene W. C. (1988) The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV Cell 53: 827-836
38. Cross S. L., Halden N. F., Lenardo M. and Leonard W. J. (1989) Functionally distinct NF-kappa B binding sites in the immunoglobulin kappa and IL-2 receptor alpha chain genes. Science 244: 466-468
39. Tan T. H., Huang G. P., Sica A., Ghosh P., Young H. A., Longo D. L. et al. (1992) Kappa B site-dependent activation of the interleukin-2 receptor alpha-chain gene promoter by human C-Rel. Mol. Cell Biol. 12: 4067-4075
40. Van Antwerp D. J., Martin S. J., Kafri T., Green D. R. and Verma I. M. (1996) Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274: 787-789
41. Faustman D., Schoenfeld D. and Ziegler R. (1991) T-lymphocyte changes linked to autoantibodies: association of insulin autoantibodies with CD4+CD45R+ lymphocyte subpopulation in prediabetic subjects. Diabetes 40: 590-597
42. Peakman M., Mahaligam M., Leslie R. D. and Vergani D. (1994) Co-expression of CD45RA (naive) and CD45RO (memory) T-cell markers. Lancet 343: 424
43. Peakman M., Mahaligam M., Leslie R. D. and Vergani D. (1993) Co-expression of CD45 RA (naive) and CD45RO (memory) T-cell markers. Lancet 342: 1296
44. Schatz D. A., Riley W. J., Maclaren N. K. and Barrett D. J. (1991) Defective inducer T cell function before the onset of insulin-dependent diabetes mellitus. J. Autoimmun. 4: 125-136
45. Faustman D., Li X., Lin H. Y., Fu Y., Eisenbarth G., Avruch J. et al. (1991) Linkage of faulty major histocompatibility complex class I to autoimmune diabetes. Science 254: 1756-1761
46. Hayashi T. and Faustman D. (1999) NOD mice are defective in proteasome production and activation of NF-kappaB. Mol. Cell. Biol. 19: 8646-8659
47. Hayashi T. and Faustman D. L. (2001) Selected contribution: Association of gender-related LMP2 inactivation with autoimmune pathogenesis. J Appl Physiol 91: 2804-2015
48. Hayashi T., Kodama S. and Faustman D. L. (2000) Reply to 'LMP2 expression and proteasome activity in NOD mice'. Nat. Med. 6: 1065-1066
49. Ryu S., Kodama S., Ryu K., Schoenfeld D. A. and Faustman D. L. (2001) Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. J. Clin. Invest. 108: 63-72
50. Mi Q. S., Ly D., Lamhamedi-Cherradi S. E., Salojin K. V., Zhou L., Grattan M. et al. (2003) Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes 52: 1967-1975
51. Guo D., Li M., Zhang Y., Yang P., Eckenrode S., Hopkins D. et al. (2004) A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat. Genet. 36: 837-841
52. Wong H. K., Kammer G. M., Dennis G. and Tsokos G. C. (1999) Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J. Immunol. 163: 1682-1689
53. Hugot J. P., Chamaillard M., Zouali H., Lesage S., Cezard J. P., Belaiche J. et al. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603
54. Ogura Y., Bonen D. K., Inohara N., Nicolae D. L., Chen F. F., Ramos R. et al. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606
55. Kessel A., Rosner I., Rozenbaum M., Zisman D., Sagiv A., Shmuel Z. et al. (2004) Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-kappa B. J. Clin. Immunol. 24: 30-36
56. Jacob C. O. and McDevitt H. O. (1988) Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 331: 356-358
57. Satoh J., Seino H. and Abo T. (1989) Recombinant human tumor necrosis factor a suppresses autoimmune diabetes in nonobese diabetic mice. J. Clin. Invest. 84: 1345-1348
58. Satoh J., Seino H., Shintani S., Tanaka S., Ohteki T., Masuda T. et al. (1990) Inhibition of type 1 diabetes in BB rats with recombinant human tumor necrosis factor-alpha. J. Immunol. 145: 1395-1399
59. Jacob C. O., Aiso S., Michie S. A., McDevitt H. O. and Acha-Orbea H. (1990) Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin I. Proc. Natl. Acad. Sci. USA 87: 968-972.
60. Grewal I. S., Grewal K. D., Wong F. S., Picarella D. E., Janeway C. A. and Flavell R. A. (1996) Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in non-obese diabetic (NOD) mice by preventing the development of autoreactive islet specific T cells. J. Exp. Med. 184: 1963-1974
61. Kassiotis G. and Kollias G. (2001) TNF and receptors in organ-specific autoimmune disease: multi-layered functioning mirrored in animal models. J. Clin. Invest. 107: 1507-1508
62. Bras A. and Aguas A. P. (1996) Diabetes-prone NOD mice are resistant to Mycobacterium avium and the infection prevents autoimmune disease. Immunology 89: 20-25
63. Harada M., Kishimoto Y. and Makino S. (1990) Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. Diabetes Res. Clin. Prac. 8: 85-89.
64. Sadelain M. W. J., Hui-Yu Q., Lauzon J. and Singh B. (1990) Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 39: 583-589
65. Qin H. Y., Sadelain M. W., Hitchon C., Lauzon J. and Singh B. (1993) Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. J. Immunol. 150: 2072-2080
66. Calcinaro F., Gambelunghe G. and Lafferty K. J. (1997) Protection from autoimmune diabetes by adjuvant therapy in the non-obese diabetic mouse: the role of interleukin-4 and interleukin-10. Immunol. Cell. Biol. 75: 467-471
67. Qin H. Y. and Singh B. (1997) BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide. J. Autoimmun. 10: 271-278
68. Wang T., Singh B., Warnock G. L. and Rajotte R. V. (1992) Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes 41: 114-117
69. McInerney M. F., Pek S. B. and Thomas D. W. (1991) Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice. Diabetes 40: 715-725
70. Lakey J. R., Singh B., Warnock G. L. and Rajotte R. V. (1994) BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice. Transplantation 57: 1213-1217
71. Shehadeh N., Etzioni A., Cahana A., Teninboum G., Gorodetsky B., Barzilai D. et al. (1997) Repeated BCG vaccination is more effective than a single dose in preventing diabetes in non-obese diabetic (NOD) mice. Isr. J. Med. Sci. 33: 711-715
72. Kalechman Y., Gafter U., Da J. P., Albeck M., Alarcon-Segovia D. and Sredni B. (1997) Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. J. Immunol. 159: 2658-2567
73. Baeuerle P. A. and Baltimore D. (1996) NF-kappa B: ten years after. Cell 87: 13-20
74. Qin H. Y., Chaturvedi P. and Singh B. (2004) In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-gamma/TNF-alpha. Int. Immunol. 16: 1723-1732
75. Valero R., Baron M. L., Guerin S., Beliard S., Lelouard H., Kahn-Perles B. et al. (2002) A defective NF-kappa B/RelB pathway in autoimmune-prone New Zealand black mice is associated with inefficient expansion of thymocyte and dendritic cells. J. Immunol. 169: 185-192
76. Sears C., Olesen J., Rubin D., Finley D. and Maniatis T. (1998) NF-κB p105 processing via the ubiquitin-proteasome pathway. J. Biol. Chem. 273: 1409-1419
77. Lin L., DeMartino G. N. and Greene W. C. (1998) Co-translational biogenesis of NF-kappa B p50 by the 26S proteasome. Cell 92: 819-828
78. Fu Y., Yan G., Shi L. and Faustman D. (1998) Antigen processing and autoimmunity. Evaluation of mRNA abundance and function of HLA-linked genes. Ann. N. Y. Acad. Sci. 842: 138-155
79. Yan G., Fu Y. and Faustman D. L. (1997) Reduced expression of Tap1 and Lmp2 antigen processing genes in the nonobese diabetic (NOD) mouse due to a mutation in their shared bidirectional promoter. J. Immunol. 159: 3068-3080
80. Tisch R., Wang B. and Serreze D. V. (1999) Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J. Immunol. 163: 1178-1187
81. Lin L., DeMartino G. N. and Greene W. C. (1998) Co-translational biogenesis of NF-κB p50 by the 26S proteasome. Cell 92: 819-828
82. Shumway S. D. and Miyamoto S. (2004) A mechanistic insight into a proteasome-independent constitutive inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor kappaB (NF-kappaB) activation pathway in WEHI-231 B-cells. Biochem. J. 380: 173-180
83. Huang R., Guo J., Li X. and Faustman D. L. (1995) Elimination of self-peptide major histocompatibility complex class I reactivity in NOD and B2-microglobulin-negative mice. Diabetes 44: 1114-1120
84. Kodama S., Kuhtreiber W., Fujimura S., Dale E. A. and Faustman D. L. (2003) Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 302: 1223-1227
85. von Herrath M. G., Coon B. and Wolfe T. (2001) Tolerance induction with agonist peptides recognized by autoaggressive lymphocytes is transient: therapeutic potential for type 1 diabetes is limited and depends on time-point of administration, choice of epitope and adjuvant. J. Autoimmun. 16: 193-199
86. Bottomly K., Luqman M., Greenbaum L., Carding S., West J., Pasqualini T. et al. (1989) A monoclonal antibody to murine CD45R distinguishes CD4 T cell populations that produce different cytokines. Eur. J. Immunol. 19: 617-623
87. Powrie F., Correa-Oliveira R., Mauze S. and Coffman R. L. (1994) Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med. 179: 589-600
88. Markiewicz M. A., Girao C., Opferman J. T., Sun J., Hu Q., Agulnik A. A. et al. (1998) Long-term T cell memory requires the surface expression of self-peptide/major histocompatibility complex molecules. Proc. Nat. Acad. Sci. USA 95: 3065-3070
89. Fu Y., Nathan D. M., Li F., Li X. and Faustman D. L. (1993) Defective major histocompatibility complex class I expression on lymphoid cells in autoimmunity. J. Clin. Invest. 91: 2301-2307
90. Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S. et al. (2000) Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1: 489-495
91. Shi Y. F., Szalay M. G., Paskar L., Sahai B. M., Boyer M., Singh B. et al. (1990) Activation-induced cell death in T cell hybridomas is due to apoptosis. Morphologic aspects and DNA fragmentation. J. Immunol. 144: 3326-3333
92. Emlen W., Niebur J. and Kadera R. (1994) Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J. Immunol. 152: 3685-3692
93. Perniok A., Wedekind F., Herrmann M., Specker C. and Schneider M. (1998) High levels of circulating early apoptotic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus 7: 113-118
94. Rose L. M., Latchman D. S. and Isenberg D. A. (1997) Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review. Br. J. Rheumatol. 36: 158-163
95. Richardson B. C., Yung R. L., Johnson K. J., Rowse P. E. and Lalwani N. D. (1996) Monocyte apoptosis in patients with active lupus. Arthritis Rheum. 39: 1432-1434
96. Lorenz H. M., Grunke M., Hieronymus T., Herrmann M., Kuhnel A., Manger B. et al. (1997) In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases [see comments]. Arthritis Rheum. 40: 306-317
97. Stummvoll G. H., Aringer M., Smolen J. S., Koller M., Kiener H. P., Steiner C. W. et al. (2000) Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology (Oxford) 39: 1341-1350
98. Van Houten N. and Budd R. C. (1992) Accelerated programmed cell death of MRL-lpr/lpr T lymphocytes. J. Immunol. 149: 2513-2517
99. Zheng L., Fisher G., Miller R. E., Peschon J., Lynch D. H. and Lenardo M. J. (1995) Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377: 348-351
100. Giroir B. P., Brown T. and Beutler B. (1992) Constitutive synthesis of tumor necrosis factor in the thymus. Proc. Natl. Acad. Sci. USA 89: 4864-488
101. Van Den Brande J. M., Peppelenbosch M. P. and Van Deventer S. J. (2002) Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann. N. Y. Acad. Sci. 973: 166-180
102. Van den Brande J. M., Braat H., van den Brink G. R., Versteeg H. H., Bauer C. A., Hoedemaeker I. et al. (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124: 1774-1785
103. Di Sabatino A., Ciccocioppo R., Cinque B., Millimaggi D., Morera R., Ricevuti L. et al. (2004) Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 53: 70-77
104. Zou J., Rudwaleit M., Brandt J., Thiel A., Braun J. and Sieper J. (2003) Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann. Rheum. Dis. 62: 561-564